<DOC>
	<DOCNO>NCT01582451</DOCNO>
	<brief_summary>The purpose study compare LY2605541 insulin glargine use follow measure participant treat 26 week : - Change participant ' overall blood sugar control - The number night time low blood sugar episodes - The number participant reach blood sugar target without low blood sugar episode night - The total number low blood sugar episode report</brief_summary>
	<brief_title>A Study LY2605541 Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have type 2 diabetes mellitus least 1 year Have receive basal insulin ( neutral protamine Hagedorn [ NPH ] , detemir , glargine ) stable dose 0 3 oral antihyperglycemic medication ( OAMs ) use specified local prescribe information least 90 day prior screen . At least 1 OAMs must dose , , half maximum daily dose allow local regulation maximally tolerate dose Have hemoglobin A1c ( HbA1c ) less equal 9.0 % screen Have body mass index ( BMI ) less equal 45.0 kilogram per square meter ( kg/m^2 ) Women childbearing potential breastfeeding , negative pregnancy test screen randomization , plan become pregnant study , practice reliable birth control least 6 week prior screen continue study 2 week last dose study drug Have routinely use insulin glargine twice daily 90 day prior study used routine , mealtime insulin therapy ( outside pregnancy ) anytime past 6 month , except shortterm treatment maximum 4 continuous week Have use rosiglitazone , pramlintide , glucagonlike peptide 1 ( GLP1 ) receptor agonist concurrently within 90 day prior screen For participant OAMs : restriction cardiac , renal , hepatic disease local product regulation Are take , take within 90 day precede screening , prescription overthecounter medication promote weight loss Have episode severe hypoglycemia within 6 month prior screen Have 1 episode diabetic ketoacidosis hyperosmolar state/coma 6 month prior screen Have cardiac disease functional status New York Heart Association Class III IV Have history renal transplantation , currently receive renal dialysis serum creatinine great equal 2 milligram per deciliter ( mg/dL ) ( 177 micromoles/liter [ mmol/L ] ) Have obvious clinical sign symptom liver disease ( exclude nonalcoholic fatty liver disease [ NAFLD ] ) , acute chronic hepatitis , non alcoholic steatohepatitis ( NASH ) , elevate liver enzyme measurement Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia , sickle cell anemia , traits hemoglobin abnormality know interfere measurement HbA1c Have active untreated cancer , remission clinically significant cancer ( basal cell squamous cell skin cancer ) less 5 year , increase risk develop cancer recurrence cancer opinion investigator Are receive chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy ( exclude topical , intranasal , intraocular , inhaled preparation ) receive therapy within 8 week immediately precede screen Have fast triglyceride great 400 mg/dL ( 4.5 mmol/L ) screening Have irregular sleep/wake cycle ( example , participant sleep day work night ) investigator 's opinion Lipidlowering medication : Are use use following : niacin preparation lipidlowering medication and/or bile acid sequestrants within 90 day prior screen lipidlowering medication dose stable least 90 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>